Meta-analysis of randomized clinical trials of Riamilovir efficacy in etiotropic therapy of influenza

The aim of the study was to carry out a meta-analysis of randomized clinical trials in order to combine the results of clinical trials on Triazavirin^® (Riamilovir) efficacy in etiotropic therapy of influenza.

Materials and methods. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works assessing medical interventions. The study included 471 patients with a confirmed diagnosis of influenza (with laboratory confirmed presence of influenza virus antigens).

Results. The conducted meta-analysis showed that the use of Triazavirin^® (Riamilovir) has a statistically significant effect on the severity of clinical symptoms in patients with influenza, therefore Riamilovir can be used in the initial therapy of adult patients with influenza.

Conclusion. Clinical studies have shown that the use of Triazavirin^® (Riamilovir) is effective both in the initial and late stages of the disease, and therefore Riamilovir can be used in the treatment of adult patients with respiratory diseases of viral etiology, in particular, those diagnosed with influenza. The meta-analysis of the collected data showed that therapy with Triazavirin^® (Riamilovir) has statistically significant advantages in various aspects both in comparison with the placebo group and with the Tamiflu^® (Oseltamivir) group.

1. Verevshchikov V.K., Shemyakina E.K., Sabitov A.U., Batskalevich N.A. Sovremennaya etiotropnaya terapiya grippa i ORVI u vzroslykh bol'nykh s otyagoshchennoj premorbidnoj patologiej. Antibiotiki i Khimioterapiya. 2018; 63 (7–8): 47–50. (in Russian)

2. Artem'ev G.A., Bondarev V.P., Borisevich S.V. i dr. Triazavirin — protivovirusnyj preparat novogo pokoleniya. Ekaterinburg: Institut organicheskogo sinteza im. I.Ya. Postovskogo UrO RAN, 2016; 257. (in Russian)

3. Page M. J., McKenzie J.E.. Bossuyt P.M., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Medicine. 2021; 18 (3)e1003583. doi: 10.1371/journal.pmed.1003583.

4. Kiselev O.I., Deeva E.G., Mel'nikova T.I. i dr. Novyj protivovirusnyj preparat Triazavirin. Rezul'taty II fazy klinicheskogo issledovaniya. Voprosy virusologii. 2012; 57 (6): 9–12. Accessed: Jun. 27, 2021. [Online]. Available: https://elibrary.ru/item.asp?id=18752159. (in Russian)

5. Mironov I.L., Ratnikova L.I. Triazavirin: izuchenie klinicheskoj effektivnosti pri grippoznoj infektsii. Poliklinika. 2015; 4: 4–5. (in Russian)

6. Popov A.F., Markelova E. V., Komarova I. A., Beniova S. N. Comparative effectiveness of riamilovir and umifenovir for treating influenza. Antibiotiki i Khimioterapiya. 2021; 66 (3–4): 35–39. doi: 10.37489/0235-2990-2021-66-3-4-35-39. (in Russian)

7. Sologub T.V., Tokin I.I., Midikari A.S., Tsvetkov V.V. Sravnitel'naya effektivnost' i bezopasnost' primeneniya protivovirusnykh preparatov v terapii bol'nykh grippom. Infektsionnye Bolezni. 2017; 15 (3): 25–32. doi: 10.20953/1729-9225-2017-3-40-47. (in Russian)

8. Ratnikova L.I. Primenene novogo otechestvennogo protivovirusnogo preparata v etiotropnoj terapii grippa. Eksperimental'naya i Klinicheskaya Farmakologiya. 2018; 81 (3): 24–27. doi: 10.30906/0869-2092-2018-81-3-24-27.

9. Higgins J.P.T. (ed.). Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021) Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2021. https://training.cochrane.org/handbook/current (accessed Jun. 13, 2021).

10. Review Manager (RevMan) [Computer program]. Version 5.4. 2020. Accessed: Jun. 13, 2021. [Online]. Available: https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman.

11. Omel'yanovskij V. V., Avksent'eva M. V., Sura M. V., Khachatryan G. R., Fedyaeva V. K. Metodicheskie rekomendatsii po otsenke kachestva statisticheskogo analiza v klinicheskikh issledovaniyakh (Utverzhdeny prikazom FGBU «TsEKKMP» Minzdrava Rossii ot «29» dekabrya 2017 g. № 181-od). Moskva: FGBU «TsEKKMP» Minzdrava Rossii», 2017. (in Russian)

12. Emel'yanova A.N., Tikhonova E.P., Kuz'mina T.Jyu. i dr. Otsenka effektivnosti protivovirusnoj terapii grippa A (H1N1) v epidemicheskie sezony 2017–2018 i 2018–2019 gg. Eksperimental'naya i Klinicheskaya Farmakologiya. 2020; 83 (3): 23–27. doi: 10.30906/0869-2092-2020-83-3-23-27. (in Russian)

13. Kas'yanenko K. V., L'vov N. I., Mal'tsev O. V., Zhdanov K. V. Nukleozidnye analogi v terapii grippa: istoriya i opyt. Zhurnal Infektologii. 2019; 11 (3): 20–26. doi: 10.22625/2072-6732-2019-11-3-20-26. (in Russian)

14. Verevshchikov V.K., Shemyakina E.K., Sabitov A.U., Khamanova Jyu.B. Vozmozhnosti etiotropnoj terapii pri grippe i ORVI s uchetom sroka gospitalizatsii bol-'nykh v statsionar i riska razvitiya vtorichnykh oslozhnenij. Antibiotiki i Khimioterapiya. 2019; 64 (3–4): 10–14. doi 10.24411/0235-2990-2019-100012. (in Russian)